On May 8th, Junlian Capital, a company invested by Junlian Capital, successfully listed on the main board of Shanghai. The opening price was 25.92 yuan/share, and the opening price was closed. Founded in 2000, WuXi PharmaTech is a giant of domestic CROs, mainly engaged in the discovery, research and development and production of small molecule chemical drugs. The data shows that in 2018, the company's CRO service market share ranks among the top ten in the world and the first in China. It is called “Huawei†in the medical field. WuXi PharmaTech has basically completed the CRO industry chain layout, providing comprehensive and integrated laboratory R&D and production services from drug discovery, development to marketization for the global pharmaceutical, biotechnology and medical device sectors. WuXi PharmaTech currently has 24 R&D and production bases/branch offices around the world, serving more than 3,000 customers including the top 20 large pharmaceutical companies in the world. During the reporting period, its top ten customers were Johnson & Johnson, Merck, Roche and Pfizer are all multinational pharmaceutical giants. In 2006, Junlian Capital met with Wu Ge, CEO of WuXi PharmaTech, and missed investment cooperation opportunities due to the size of the fund at that time. In 2015, Junlian Capital invested tens of millions of dollars in the privatization of the company. According to reports, medical services are the core link of the medical and health industry chain. Junlian Capital has a long-term and systematic layout in this field, involving pharmaceutical R&D and clinical CRO, third-party medical laboratories, medical/medical chain, genetic testing, and specialists. Hospitals, artificial intelligence medical imaging, cellular immunotherapy, etc., among which the invested companies Yixintang, Yaoming Biological, Berry Gene and Jinyu Medicine have all been successfully listed. Junlian Capital has been in the medical service field for ten years. Starting from medical service investment, Junlian Capital Medical Investment has gradually expanded into pharmaceutical, biotechnology, medical equipment and other sub-sectors and has invested in several leading projects. At present, Junlian Capital has built a medical and health investment base around the core areas, and on this basis, established a professional medical industry investment team and established a medical health investment professional fund. (China Securities Journal)
Our PP Resin is used to manufacture various port with different models, such as Single Port, Double Port ,Small Port etc . We have a excellent supply-chain in our product materials. If you have any specific requirements, let us know, we will do our best to meet your requirements.In our website,we provide the images and basic parameters for each products. We are a professional chinese manufacturer of medical packaging and look forward to your inquiries! Pp Resin For Port,Polypropylene Pp Copolymer Resin,Pp Granules Pp Resin,Pp Pellets Pp Resin Suzhou CRH New Material Technology Co.,Ltd. , https://www.crh-health.com